Aug 13, 2020
Biostage Reports Second Quarter 2020 Financial Results
Mar 27, 2020
Biostage Reports 2019 Financial Results
Mar 20, 2020
Biostage Announces IND Approval from FDA for its Lead Product Candidate Cellspan(TM) Esophageal Implant
Feb 20, 2020
Biostage Submitted Official Response to FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan(TM) Esophageal Implant
Jan 02, 2020
Biostage Provides Update on FDA Investigational New Drug Application for its Lead Product Candidate Cellspan(TM) Esophageal Implant
Dec 03, 2019
Biostage Receives Response from the FDA for Investigational New Drug Application for its Lead Product Candidate Cellspan(TM) Esophageal Implant
Nov 12, 2019
Biostage Reports Third Quarter 2019 Financial Results
Nov 06, 2019
­­Biostage to Host Conference Call to Discuss Third Quarter 2019 Financial Results and Business Update
Oct 30, 2019
Biostage Submits Investigational New Drug (IND) Application for Lead Product Candidate Cellspan(TM) Esophageal Implant for Treatment of Esophageal Conditions
Aug 13, 2019
Biostage Reports Second Quarter 2019 Financial Results
Aug 07, 2019
Biostage to Host Conference Call to Discuss Second Quarter 2019 Financial Results and Business Update
May 14, 2019
Biostage Reports First Quarter 2019 Financial Results
Mar 21, 2019
Biostage to Host Conference Call to Discuss 2018 Financial Results and Business Update
Jan 28, 2019
First-In-Human Case Using Biostage's Bioengineered Esophageal Implant is Presented at Major Surgical Meeting
Nov 08, 2018
Biostage Reports 2018 Third Quarter Financial Results
Nov 07, 2018
Ms. Ting Li Appointed to Biostage Board of Directors
Nov 06, 2018
Biostage awarded $1.1 million Phase II NIH SBIR Fast-Track grant to develop Cellspan(TM) Esophageal Implant (CEI) as a novel treatment for pediatric esophageal atresia
Nov 02, 2018
Biostage to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Operations
Aug 14, 2018
Biostage Reports 2018 Second Quarter Financial Results
Aug 09, 2018
Biostage to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Operations